MMAE (monomethyl auristatin E) is an antimitotic agent that binds to tubulin and inhibits the assembly of microtubules. Mc-VC-PAB-MMAE is a thiol reactive derivative of MMAE that containing a cathepsin cleavable valine-citruline p-aminobenzylcarbamate linkage. Mc-VC-PAB-MMAE is used to prepare antibody-drug conjugates, such as brentuximab vedotin (Seattle Genetics). This BSA-MMAE conjugate is designed with similar linker chemistry as ADC and is synthesized at CellMosaic for our customers' usage in immunization or immunoassay. First, thiol functional groups are introduced to the BSA followed by reaction of the maleimide group of Mc-VC-PAB-MMAE to form the conjugate. The final conjugate is lyophilized from phosphate buffered saline containing sugar-based stabilizer for easy shipping and storage.
The product is sold as 1 vial of 1 mg (Cat# CM52113_1MG) or 5 vials of 1 mg (Cat# CM52113_5MG). For bulk orders, please contact us for a quote.
- Chemical name: BSA-MMAE (monomethyl auristatin E) Conjugate
- Chemical formula: N/A
- Molecular weight: 71KDa CAS number: N/A
- Physical appearance: white to off-white preservative-free lyophilized powder in a 2.0 mL centrifuge tube
- Storage temp.: -20°C
- Purity: ≥ 99 % of conjugates by HPLC
- Drug to BSA ratio: ~4